Acer Therapeutics Inc. (ACER): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACER Stock Summary
- ACER's price/sales ratio is 110.07; that's higher than the P/S ratio of 97.61% of US stocks.
- ACER's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 4% of US stocks.
- As for revenue growth, note that ACER's revenue has grown -60% over the past 12 months; that beats the revenue growth of just 3.06% of US companies in our set.
- Stocks that are quantitatively similar to ACER, based on their financial statements, market capitalization, and price volatility, are GANX, VTVT, FKWL, DAIO, and ALLT.
- Visit ACER's SEC page to see the company's official filings. To visit the company's web site, go to www.acertx.com.
ACER Valuation Summary
- In comparison to the median Healthcare stock, ACER's price/sales ratio is 5251.22% higher, now standing at 109.7.
- Over the past 205 months, ACER's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ACER.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACER | 2023-01-20 | 109.7 | -3.2 | -1.9 | -1.9 |
| ACER | 2023-01-19 | 108.6 | -3.2 | -1.8 | -1.9 |
| ACER | 2023-01-18 | 109.7 | -3.2 | -1.9 | -1.9 |
| ACER | 2023-01-17 | 111.4 | -3.3 | -1.9 | -2.0 |
| ACER | 2023-01-13 | 136.4 | -4.0 | -2.3 | -2.4 |
| ACER | 2023-01-12 | 138.6 | -4.1 | -2.3 | -2.4 |
ACER Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at -291.31%.
- The 4 year net cashflow from operations growth rate now stands at -223.3%.
- Its 5 year net income to common stockholders growth rate is now at -291.31%.
The table below shows ACER's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.36 | -23.37391 | -21.27363 |
| 2022-06-30 | 0.36 | -22.24394 | -19.53969 |
| 2022-03-31 | 0.36 | -6.153168 | -19.94169 |
| 2021-12-31 | 1.26 | -0.134909 | -15.37399 |
| 2021-09-30 | 0.9 | -2.594543 | -17.19103 |
| 2021-06-30 | 3.998133 | 0.915877 | -16.90639 |
ACER Price Target
For more insight on analysts targets of ACER, see our ACER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.75 (Moderate Buy) |
ACER Stock Price Chart Interactive Chart >
ACER Price/Volume Stats
| Current price | $2.35 | 52-week high | $4.56 |
| Prev. close | $2.42 | 52-week low | $1.11 |
| Day low | $2.35 | Volume | 3,283 |
| Day high | $2.35 | Avg. volume | 610,799 |
| 50-day MA | $2.31 | Dividend yield | N/A |
| 200-day MA | $1.79 | Market Cap | 37.47M |
Acer Therapeutics Inc. (ACER) Company Bio
Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest ACER News From Around the Web
Below are the latest news stories about ACER THERAPEUTICS INC that investors may wish to consider to help them evaluate ACER as an investment opportunity.
After A -20.98% Drop In The Last Week, Does Acer Therapeutics Inc. (NASDAQ: ACER) Still Make Sense To Buy?During the last session, Acer Therapeutics Inc. (NASDAQ:ACER)’s traded shares were 0.48 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $2.41, reflecting an intraday gain of 0.84% or $0.02. The 52-week high for the ACER share is $4.56, that puts it down … After A -20.98% Drop In The Last Week, Does Acer Therapeutics Inc. (NASDAQ: ACER) Still Make Sense To Buy? Read More » |
Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should KnowAcer Therapeutics Inc. (ACER) closed at $2.39 in the latest trading session, marking a -0.83% move from the prior day. |
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer TherapeuticsDyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article. |
5 Stocks to Buy as the Drug Industry Bets Big on InnovationInnovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today! |
ACER Price Returns
| 1-mo | -8.56% |
| 3-mo | 92.62% |
| 6-mo | 68.42% |
| 1-year | 17.50% |
| 3-year | -41.25% |
| 5-year | -87.94% |
| YTD | -6.37% |
| 2022 | 10.09% |
| 2021 | -12.98% |
| 2020 | -34.66% |
| 2019 | -80.07% |
| 2018 | 45.27% |
Loading social stream, please wait...